Search

The sequestration of uranium, particularly from the deposited bones, has been an incomplete task in chelation therapy for actinide decorporation. Part of the reason is that all previous decorporation ligands are not delicately designed to meet the coordination requirement of uranyl cations. Herein, guided by DFT calculation, we elaborately design a hexadentate ligand (TAM-2LI-MAM 2 ), whose preorganized planar oxo-donor configuration perfectly matches the typical coordination geometry of the uranyl cation. This leads to an ultrahigh binding affinity to uranyl supported by an in vitro desorption experiment of uranyl phosphate. Administration of this ligand by prompt intraperitoneal injection demonstrates its uranyl removal efficiencies from the kidneys and bones are up to 95.4% and 81.2%, respectively, which notably exceeds all the tested chelating agents as well as the clinical drug ZnNa 3 -DTPA, setting a new record in uranyl decorporation efficacy.

In conjunction with theoretical calculations, the in vitro and in vivo uranyl binding capabilities of a bidentate picolinate (Pic) ligand and its pentadentate derivative (H2dpa) are investigated. The planar N3O2-donor configuration of H2dpa matches the typical pentagonal-bipyramid coordination geometry of uranyl, demonstrating a remarkable removal preference for uranyl in the kidneys. [ABSTRACT FROM AUTHOR]